Ling Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ling Zhou has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Chi Luxiang
Department of Cardiology,Southwest Hospital,Third Military Medical University,Chongqing,400038,China
1 shared publication- Dao-Pei Lu
The Fifth People's Hospital of Shanghai, Hematology Department, Fudan University, No. 801 Heqing Road, Minhang County, Shanghai, 200240, China.
1 shared publication - Guoqiang Zhuang
Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences, Beijing 100085, China
1 shared publication - Haijun Du
Xinjiang Key Laboratory of Clean Conversion and High Value Utilization of Biomass Resources, College of Chemistry and Chemical Engineering, Yili Normal University, Yining 835000, P. R. China
1 shared publication He Guoxiang
Department of Cardiology,Southwest Hospital,Third Military Medical University,Chongqing,400038,China
1 shared publication- Houyuan Hu
Department of Cardiology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China
1 shared publication
Latest Publications
- 13 March 2020
- Published by Wiley in Clinical Transplantation
- Vol. 34 (6) , e13856
Incidence, risk factors, and clinical outcomes associated with Epstein‐Barr virus‐DNAemia and Epstein‐Barr virus‐associated disease in patients after haploidentical allogeneic stem cell transplantation: A single‐center study
Human leukocyte antigen (HLA)‐haploidentical hematopoietic stem cell transplantation (haplo‐HSCT) is an effective alternative to HLA‐matched transplantation. However, Epstein‐Barr virus (EBV) infection causes morbidity and mortality in patients undergoing haplo‐HSCT. Here, we retrospectively evaluated the incidence and risk factors of EBV‐DNAemia and EBV‐associated diseases in 131 patients who underwent haplo‐HSCT. Patients were classified into the no EBV infection groups, EBV‐DNAemia group and EBV‐associated disease group. Cumulative incidences of acute graft‐vs‐host disease, EBV infections, overall survival (OS), and relapse were analyzed. The cumulative incidences of EBV‐DNAemia and EBV‐associated disease were 26.9% and 33.3%, respectively. In multivariate analysis, cytomegalovirus (CMV)‐DNAemia was confirmed as an independent risk factor associated with EBV‐DNAemia and EBV‐associated disease. Patients with EBV‐associated disease had higher transplant‐related mortality (TRM) rates and lower OS rates, but similar relapse rates. Overall, these findings demonstrated the cumulative incidences of EBV‐DNAemia and EBV‐associated disease and identified correlations of EBV infection with TRM, relapse, and OS. Additionally, CMV‐DNAemia was a risk factor for EBV‐DNAemia and EBV‐associated disease.
- 13 March 2020
- Published by Wiley in Clinical Transplantation
- Vol. 34 (6) , e13856
Incidence, risk factors, and clinical outcomes associated with Epstein‐Barr virus‐DNAemia and Epstein‐Barr virus‐associated disease in patients after haploidentical allogeneic stem cell transplantation: A single‐center study
Human leukocyte antigen (HLA)‐haploidentical hematopoietic stem cell transplantation (haplo‐HSCT) is an effective alternative to HLA‐matched transplantation. However, Epstein‐Barr virus (EBV) infection causes morbidity and mortality in patients undergoing haplo‐HSCT. Here, we retrospectively evaluated the incidence and risk factors of EBV‐DNAemia and EBV‐associated diseases in 131 patients who underwent haplo‐HSCT. Patients were classified into the no EBV infection groups, EBV‐DNAemia group and EBV‐associated disease group. Cumulative incidences of acute graft‐vs‐host disease, EBV infections, overall survival (OS), and relapse were analyzed. The cumulative incidences of EBV‐DNAemia and EBV‐associated disease were 26.9% and 33.3%, respectively. In multivariate analysis, cytomegalovirus (CMV)‐DNAemia was confirmed as an independent risk factor associated with EBV‐DNAemia and EBV‐associated disease. Patients with EBV‐associated disease had higher transplant‐related mortality (TRM) rates and lower OS rates, but similar relapse rates. Overall, these findings demonstrated the cumulative incidences of EBV‐DNAemia and EBV‐associated disease and identified correlations of EBV infection with TRM, relapse, and OS. Additionally, CMV‐DNAemia was a risk factor for EBV‐DNAemia and EBV‐associated disease.
- Open Access
- 16 March 2011
- Published by Springer Nature in Science China Life Sciences
- Vol. 54 (3) , 263-266
Specific cellular immune responses in mice immunized with DNA, adeno-associated virus and adenoviral vaccines of Epstein-Barr virus-LMP2 alone or in combination
Cellular immune responses, particularly those associated with CD3+CD8+ cytotoxic T lymphocytes (CTL), are critical factors in controlling viral infection. Nasopharyngeal carcinoma (NPC) is closely associated with persistent Epstein-Barr virus (EBV) infection. NPC vaccine studies have focused on enhancing specific antiviral CTL responses. In this study, three vaccines capable of expressing the EBV-latent membrane protein 2 (LMP2) (a DNA vector, an adeno-associated virus (AAV) vector, and a replication-defective adenovirus serotype 5 (Ad5) vector) were respectively used to immunize female Balb/c mice (4–6 weeks old) at weeks 0, 2 and 4, either alone or in combination. Our results suggest that combined immunization with DNA, AAV, and adenovirus vector vaccines induced specific cellular immunity more effectively than any of these vectors alone or a combination of two of the three, constituting a sound vaccine strategy for the prevention and treatment of NPC.
- 16 March 2011
- Published by Springer Nature in Science China Life Sciences
- Vol. 54 (3) , 263-266
Open AccessSpecific cellular immune responses in mice immunized with DNA, adeno-associated virus and adenoviral vaccines of Epstein-Barr virus-LMP2 alone or in combination
Cellular immune responses, particularly those associated with CD3+CD8+ cytotoxic T lymphocytes (CTL), are critical factors in controlling viral infection. Nasopharyngeal carcinoma (NPC) is closely associated with persistent Epstein-Barr virus (EBV) infection. NPC vaccine studies have focused on enhancing specific antiviral CTL responses. In this study, three vaccines capable of expressing the EBV-latent membrane protein 2 (LMP2) (a DNA vector, an adeno-associated virus (AAV) vector, and a replication-defective adenovirus serotype 5 (Ad5) vector) were respectively used to immunize female Balb/c mice (4–6 weeks old) at weeks 0, 2 and 4, either alone or in combination. Our results suggest that combined immunization with DNA, AAV, and adenovirus vector vaccines induced specific cellular immunity more effectively than any of these vectors alone or a combination of two of the three, constituting a sound vaccine strategy for the prevention and treatment of NPC.
- 1 October 2005
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 16 (6) , 413-418
The clinical and hemodynamic results of mitral balloon valvuloplasty for patients with mitral stenosis complicated by severe pulmonary hypertension
- 1 October 2005
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 16 (6) , 413-418
The clinical and hemodynamic results of mitral balloon valvuloplasty for patients with mitral stenosis complicated by severe pulmonary hypertension